President Trump has selected physician Heidi Overton for the role of Food and Drug Administration commissioner, a position that will oversee which drugs reach American patients, regulate food products, and manage policies on vaccines and other health interventions.

The nominee, described by President Trump as a “rockstar,” was previously a White House policy adviser who worked closely with Health Secretary Kennedy and Mehmet Oz. If confirmed by the Senate, Overton would become the next FDA commissioner.

Overton, a board-certified physician in public health and general preventive medicine, earned her medical degree from the University of New Mexico and a doctorate in clinical investigation from Johns Hopkins University. She served as a White House fellow during President Trump’s first term and later became chief policy officer at the America First Policy Institute before returning to the White House.

The nomination follows ongoing challenges for the FDA after former Commissioner Dr. Marty Makary resigned in May, leaving unresolved disputes over COVID-19 vaccines, antidepressants, vaping products, rare-disease drugs, and ultra-processed foods. Overton has been a vocal advocate within the administration for revising childhood-vaccine recommendations and has also argued for additional safety measures around chemical abortions, including requiring in-person evaluations to determine medical appropriateness and screening patients for complications.

Senator Bill Cassidy, chairman of the Senate committee reviewing Overton’s nomination, expressed concerns about her managerial experience and role in vaccine policy. He stated that Overton’s lack of leadership experience does not prepare her for leading a large agency facing staffing and morale issues. The White House indicated it had considered multiple candidates before selecting Overton, with industry groups and advocacy organizations holding differing views on the nominee’s suitability regarding potential restrictions on abortion drug access.

This nomination has raised questions about how the FDA will balance the administration’s health agenda with its responsibilities to ensure safe and effective medical products.